Crescent Biopharma, Inc.
NASDAQ: CBIO · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Crescent Biopharma, Inc. (CBIO) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.91M | $18.42M | $5.28M | $57.26M | $48.46M | $42.39M | $128.58M | $214.84M | $167.97M | $142.83M | $94.35M | $51.81M | $45.32M | $35.62M | $240.29M |
| Cash & equivalents | $28.17M | $17.37M | $2.31M | $55.20M | $46.80M | $40.04M | $123.92M | $209.92M | $158.20M | $137.04M | $90.25M | $47.87M | $41.79M | $34.77M | $213.19M |
| Current assets | $28.37M | $17.97M | $4.88M | $56.12M | $47.24M | $40.52M | $127.22M | $212.27M | $162.53M | $138.27M | $90.79M | $50.71M | $43.79M | $34.80M | $236.66M |
| Total liabilities | $20.45M | $5.89M | $2.38M | $6.46M | $7.99M | $7.09M | $8.88M | $9.38M | $13.77M | $14.61M | $12.74M | $8.88M | $6.90M | $51.10M | $37.28M |
| Current liabilities | $16.41M | $5.69M | $2.28M | $6.46M | $7.75M | $6.33M | $8.17M | $8.76M | $10.95M | $12.43M | $11.82M | $8.88M | $6.84M | $9.61M | $36.07M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | — | $37.48M | — |
| Shareholder equity | $8.46M | $12.53M | $2.91M | $50.80M | $40.47M | $35.30M | $119.70M | $205.46M | $154.20M | $128.22M | $81.60M | $42.93M | $38.41M | $-15.48M | $203.01M |
| Retained earnings | $-56.33M | $-52.67M | $-63.28M | $-74.40M | $-87.17M | $-118.98M | $-152.28M | $-200.55M | $-258.44M | $-309.47M | $-372.90M | $-419.59M | $-456.49M | $-17.87M | $-171.81M |
| Accounts receivable | — | — | $94754.00 | $22334.00 | $38683.00 | $268659.00 | $101955.00 | $413122.00 | $185953.00 | $2149.00 | $1347.00 | $144016.00 | $175820.00 | $136580.00 | $18.00M |
| Inventory | — | — | — | $-77.00 | — | $198836.00 | — | $-405.00 | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Crescent Biopharma, Inc.'s revenue?
Crescent Biopharma, Inc.'s trailing twelve-month revenue is $11.88M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is CBIO?
In its most recent fiscal year, CBIO ran a gross margin of 100.00%, an operating margin of -1,407.52%, and a net margin of -1,419.61%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CBIO generate?
CBIO produced $-72.45M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CBIO's balance sheet healthy?
CBIO holds $213.19M in cash and equivalents against — in long-term debt, on $203.01M of shareholder equity. That debt is best read against the cash flow the business throws off each year.